Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyBCBS Massachusetts Respiratory Coverage | OpenPaye…
    Ask Trek AI about this page
    CurrentBlue Cross Blue Shield - MassachusettsPolicy 808

    Infectious Disease Laboratory Testing -Respiratory

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 808 alerts

    Get alerted when Policy 808 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs medical necessity and authorization requirements for bacterial, streptococcal, viral, and multiplex respiratory infectious disease laboratory tests for eligible commercial and Medicare Advantage members.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyInfectious Disease Laboratory Testing -Respiratory
    Policy CodePolicy 808
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or prior authorization for services described in this policy when performed in the inpatient setting.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    4Respiratory test categories with medical necessity criteria
    InpatientPrior authorization requirement
    6+ targetsMultiplex respiratory panel threshold
    5 or fewerSmall multiplex viral panel threshold
    All otherOther indications designated investigational

    Medical Necessity Coverage Criteria

    Bacterial Respiratory Infection/Pneumonia Target Panels

    Bacterial respiratory infection/pneumonia target panels are medically necessary when ALL of the following are met:

    Required criteria

    • Qualifying clinical criterion: New or worsening lung infiltrates; moderate to severe upper respiratory illness; receipt of empiric antibiotics before obtaining cultures; or possible multidrug-resistant bacteria or polymicrobial infection.

      At least one is required.

    • Management impact: Results of the testing will influence the member's clinical management.

    Group A Streptococcus Pharyngitis Tests

    Group A streptococcus pharyngitis tests are medically necessary when ALL of the following are met:

    Required criteria

    • Qualifying clinical feature: Acute pharyngitis; fever; tonsillopharyngeal inflammation; patchy tonsillopharyngeal exudates; palatal petechiae; anterior cervical lymphadenitis; or scarlatiniform rash.

      At least one is required.

    • Viral features absent: The member does not have clinical and epidemiological features that strongly suggest a viral etiology, such as cough, rhinorrhea, hoarseness, and oral ulcers.
    • Management impact: Results of the testing will influence the member's clinical management.

    Syndromic/Multiplex Respiratory Panels with 6 or More Targets

    Syndromic/multiplex respiratory panels with 6 or more targets are medically necessary when ALL of the following are met:

    Required criteria

    • Qualifying severity or risk criterion: The member is immunocompromised, has severe pneumonia, or has an exacerbation of airway disease.

      At least one is required.

    • Management impact: Results of the testing will influence the member's clinical management.

    SARS-CoV-2, RSV, Influenza A/B, or Multiplex Respiratory Viral Panels with 5 or Fewer Targets

    SARS-CoV-2, RSV, influenza A/B, and multiplex respiratory viral panels with 5 or fewer targets are medically necessary when ALL of the following are met:

    Required criteria: The member presents in the outpatient setting with signs or symptoms of an acute respiratory infection, and testing results will influence the member's clinical management.5 or fewer targets for multiplex respiratory viral panels

    This category also includes SARS-CoV-2, RSV, or influenza A/B testing.

    Bacterial respiratory infection/pneumonia target panels are considered investigational for all indications other than the stated medically necessary criteria. Coverage therefore requires the member to be an outpatient with signs or symptoms of an acute respiratory infection, at least one qualifying clinical finding, and an expectation that results will influence clinical management.

    Group A streptococcus pharyngitis tests are considered investigational for all indications other than the stated medically necessary criteria. The covered evaluation requires an outpatient qualifying clinical feature, no clinical or epidemiological features strongly suggesting a viral etiology, and an expectation that results will influence clinical management.

    Syndromic or multiplex respiratory panels with 6 or more targets are considered investigational for all indications other than the stated medically necessary criteria. Covered use is limited to outpatients with signs or symptoms of an acute respiratory infection who are immunocompromised, have severe pneumonia, or have an airway-disease exacerbation, when results will influence clinical management.

    SARS-CoV-2, RSV, influenza A/B, and multiplex respiratory viral panels with 5 or fewer targets are considered investigational for all indications other than the stated medically necessary criteria. Covered use requires outpatient signs or symptoms of an acute respiratory infection and an expectation that results will influence clinical management.

    Covered Clinical Indications and Evidence-Based Contexts

    Bacterial Respiratory Infection/Pneumonia Panel Indications

    Covered indications for bacterial respiratory infection/pneumonia target panels require ALL of the following:

    Outpatient acute respiratory infection

    • Qualifying clinical circumstance: New or worsening lung infiltrates; moderate to severe upper respiratory illness; empiric antibiotics received before cultures were obtained; or possible multidrug-resistant bacteria or polymicrobial infection.
    • Management impact: Results will influence clinical management.

    Group A Streptococcal Pharyngitis Indications

    Group A streptococcal pharyngitis testing is covered when ALL of the following are present:

    Outpatient pharyngitis evaluation

    Covered and Applicable Coding

    Bacterial Respiratory Infection/Pneumonia Target PanelsCPTCovered
    86581Streptococcus pneumoniae antibody (IgG), serotypes, multiplex immunoassay, quantitative.
    87485Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, direct probe technique.
    87564Infectious agent detection by nucleic acid (DNA or RNA); Mycobacterium tuberculosis, rifampin resistance, amplified probe technique.
    Group A Streptococcus Pharyngitis TestsCPTCovered
    87428CPT code listed under Group A streptococcus pharyngitis tests; description is not fully rendered in the source extract.
    87631CPT code listed under Group A streptococcus pharyngitis tests; description is not fully rendered in the source extract.
    87636CPT code listed under Group A streptococcus pharyngitis tests; description is not fully rendered in the source extract.
    87637CPT code listed under Group A streptococcus pharyngitis tests; description is not fully rendered in the source extract.
    Syndromic/Multiplex Respiratory Panels with 6 or More TargetsCPTCovered
    87482Infectious agent detection by nucleic acid (DNA or RNA); Candida species, quantification
    87486Infectious agent detection by nucleic acid (DNA or RNA); Chlamydia pneumoniae, amplified probe technique.
    87500Infectious agent detection by nucleic acid (DNA or RNA); vancomycin resistance (eg, enterococcus species van A, van B), amplified probe technique.
    87501Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or subtypes, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, first 2 types or subtypes.
    87502Infectious agent detection by nucleic acid (DNA or RNA); influenza virus, for multiple types or subtypes, includes multiplex reverse transcription, when performed, and multiplex amplified probe technique, each additional influenza virus type or subtype beyond 2.
    87503Infectious agent detection by nucleic acid (DNA or RNA); each additional respiratory virus nucleic acid sequence detected beyond the first 2.
    87540Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, direct probe technique.
    87541Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, amplified probe technique.
    87542Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification.
    87551Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique.
    1–10 of 15
    1/2
    SARS-CoV-2, RSV, or Influenza A/B, or Multiplex Respiratory Viral Panels with 5 or Fewer TargetsCPTCovered
    No codes listed
    CPT CodesCPT
    87541Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, amplified probe technique.
    87542Infectious agent detection by nucleic acid (DNA or RNA); Legionella pneumophila, quantification.
    87551Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, amplified probe technique.
    87552Infectious agent detection by nucleic acid (DNA or RNA); Mycobacteria species, quantification.
    87580Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, direct probe technique.
    87581Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, amplified probe technique.
    87582Infectious agent detection by nucleic acid (DNA or RNA); Mycoplasma pneumoniae, quantification.
    87631Infectious agent detection by nucleic acid (DNA or RNA); respiratory virus, including multiplex reverse transcription when performed and multiplex amplified probe technique, multiple types or subtypes, 3-5.
    87640Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, amplified probe technique.
    87641Infectious agent detection by nucleic acid (DNA or RNA); Staphylococcus aureus, methicillin resistant, amplified probe technique.
    1–10 of 16
    1/2
    SARS-CoV-2, RSV, or Influenza A/B, OR Multiplex Respiratory Viral Panels with 5 or Fewer Targets CPT Codesmixed
    86328Immunoassay for infectious agent antibody(ies), qualitative or semiquantitative, single step method; SARS-CoV-2.
    86408Neutralizing antibody, SARS-CoV-2; screen.
    86409Neutralizing antibody, SARS-CoV-2; titer.
    86413SARS-CoV-2 antibody, quantitative.
    86769Antibody; SARS-CoV-2.
    87275Infectious agent antigen detection by immunofluorescent microscope; respiratory syncytial virus.
    87276Infectious agent antigen detection by immunofluorescent microscope; severe acute respiratory syndrome coronavirus.
    87400Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple step method; respiratory syncytial virus.
    87420Infectious agent antigen detection by enzyme immunoassay technique, qualitative or semiquantitative, multiple step method; respiratory virus.
    87426Infectious agent antigen detection by immunoassay with direct optical observation; SARS-CoV-2.
    1–10 of 29
    1/3
    Multiplex Respiratory Panel Target Count
    Target threshold6 or more respiratory targets
    Panel categoryMultiplex respiratory panel
    Clinical classificationSyndromic or multiplex respiratory panels testing for six or more respiratory targets
    Multiplex Respiratory Viral Panel Target Count
    Target threshold5 or fewer respiratory viral targets
    Panel category

    Authorization and Coverage Risk

    Prior Authorization

    Obtain inpatient prior authorization

    Precertification or prior authorization is required for all products when a service described in this policy is performed in the inpatient setting.

    Denial Risk

    Bacterial panel criteria must be met

    Bacterial respiratory infection/pneumonia target panels are investigational when the member does not meet the stated outpatient acute respiratory infection criteria or when testing results will not influence clinical management.

    • Document signs or symptoms of an acute respiratory infection in the outpatient setting.
    • Document at least one qualifying criterion: new or worsening lung infiltrates; moderate to severe upper respiratory illness; empiric antibiotics before cultures; or possible multidrug-resistant bacteria or polymicrobial infection.
    • Confirm that results will influence clinical management.

    Policy Scope and Clinical Background

    This policy addresses laboratory testing for acute respiratory infections, including bacterial respiratory infection and pneumonia panels, group A streptococcal pharyngitis tests, syndromic or multiplex respiratory panels with 6 or more targets, and targeted respiratory viral testing for SARS-CoV-2, RSV, influenza A/B, or multiplex respiratory viral panels with 5 or fewer targets. Medical necessity depends on the member’s clinical presentation, relevant risk or severity features, and whether test results are expected to influence clinical management.

    Respiratory Panel Definitions

    Syndromic/Multiplex Respiratory Panel With 6 or More Targets
    DefinitionA syndromic or multiplex respiratory panel testing for six or more respiratory targets
    Minimum target count6 respiratory targets
    CategorySyndromic or multiplex respiratory panel
    Multiplex Respiratory Viral Panel With 5 or Fewer Targets
    DefinitionA multiplex respiratory viral panel testing for five or fewer respiratory viral targets
    Target limit5 or fewer targets
    Included viral target

    Non-Covered and Investigational Indications

    The following services are not covered because they are designated investigational for indications outside the policy’s stated medical necessity criteria: bacterial respiratory infection/pneumonia target panels; group A streptococcus pharyngitis tests; syndromic or multiplex respiratory panels with 6 or more targets; and SARS-CoV-2, RSV, influenza A/B, or multiplex respiratory viral panels with 5 or fewer targets.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyInfectious Disease Laboratory Testing -Respiratory
    Policy CodePolicy 808
    Change TypeNo material change
    Effective DateOct 1, 2026
    Last ReviewOct 1, 2026
    Next Review DateN/A
    Key ActionObtain precertification or prior authorization for services described in this policy when performed in the inpatient setting.
    SourceLink
    On This Page
    Medical Necessity Coverage CriteriaCovered Clinical Indications and Evidence-Based ContextsCovered and Applicable CodingAuthorization and Coverage RiskPolicy Scope and Clinical BackgroundRespiratory Panel DefinitionsNon-Covered and Investigational Indications
  1. Clinical feature: Acute pharyngitis; fever; tonsillopharyngeal inflammation; patchy tonsillopharyngeal exudates; palatal petechiae; anterior cervical lymphadenitis; or scarlatiniform rash.
  2. Strong viral features absent: The member does not have clinical and epidemiological features that strongly suggest a viral etiology, such as cough, rhinorrhea, hoarseness, or oral ulcers.
  3. Management impact: Results will influence clinical management.
  4. Large Multiplex Respiratory Panel Indications

    Large multiplex respiratory panels are covered when ALL of the following are present:

    Large multiplex panel indication

    • Risk or severity criterion: The member is immunocompromised, has severe pneumonia, or has an exacerbation of airway disease.
    • Management impact: Results will influence clinical management.

    Small Viral Respiratory Panel Indications

    Small viral respiratory panels and targeted respiratory virus tests are covered when ALL of the following are present:

    Small viral panel indication: The member presents in the outpatient setting with signs or symptoms of an acute respiratory infection, and results will influence clinical management.5 or fewer targets for multiplex respiratory viral panels

    Includes SARS-CoV-2, RSV, and influenza A/B testing.

    IDSA Bacterial Respiratory NAAT Contexts

    Bacterial respiratory NAATs may be useful in ANY of the following clinical contexts:

    Clinical context: New or worsening lung infiltrates; moderate to severe illness; empiric antibiotics given before cultures were obtained; or concern for multidrug-resistant bacteria or polymicrobial infection.

    Severe Community-Acquired Pneumonia Multiplex PCR Recommendation

    Multiplex PCR testing is recommended when ALL of the following apply:

    Severe community-acquired pneumonia context: The patient has severe community-acquired pneumonia; testing is performed on a lower respiratory tract sample, such as sputum or an endotracheal aspirate; and non-standard antibiotics are being considered or prescribed.

    IDSA Group A Streptococcus Testing Guidance

    Group A Streptococcus pharyngitis testing should include the following:

    Recommended testing approach

    • Testing method: Rapid antigen detection testing or culture, performed using a throat swab.
    • Clinical assessment limitation: Clinical features alone generally do not reliably distinguish group A Streptococcus from viral pharyngitis unless overt viral features are present, such as rhinorrhea, cough, oral ulcers, or hoarseness.

    Multiplex Viral NAAT Contexts

    Multiplex viral nucleic acid amplification testing may be appropriate in ANY of the following contexts:

    Clinical context: The patient is immunocompromised or critically ill with pneumonia; has an asthma or chronic obstructive pulmonary disease exacerbation complicated by respiratory infection; or is a selected transplant recipient at increased risk for respiratory viral infection, particularly early after transplantation, during increased immunosuppression, or during respiratory virus season.

    Pediatric Bronchiolitis Testing Context

    Additional respiratory testing may be warranted when:

    Bronchiolitis exception: An infant or child with bronchiolitis experiences unexpected clinical worsening.

    Routine laboratory testing is not advised when bronchiolitis is diagnosed from the clinical history and physical examination alone.

    CDC Respiratory Testing Considerations

    Respiratory testing considerations include the following:

    Respiratory testing considerations: Consider RSV in patients with respiratory illness, particularly during RSV season, and perform early testing in people who experience symptoms of COVID-19.
    Multiplex respiratory viral panel
    Clinical classificationPanels testing for five or fewer respiratory viral targets
    Respiratory Virus Multiplex Panel
    Target range3-5 targets
    Procedure code87631
    Respiratory viruses listedAdenovirus, influenza virus, coronavirus, metapneumovirus, parainfluenza virus, respiratory syncytial virus, and rhinovirus
    Respiratory Virus Multiplex Panel
    Target range12-25 targets
    Procedure code87634
    Panel descriptionRespiratory virus multiplex testing using multiplex reverse transcription, when performed, and multiplex amplified probe technique
    Nonspecific Multiplex Respiratory Panel
    Lower target range2-5 targets
    Higher target range6-11 targets
    Lower-range procedure code87798
    Higher-range procedure code87799
    Syndromic/Multiplex Respiratory Panel
    Target threshold6 or more targets
    Panel categorySyndromic/multiplex respiratory panel
    DefinitionA respiratory panel testing for six or more respiratory targets
    Denial Risk

    Group A streptococcus criteria must be met

    Group A streptococcus pharyngitis testing is investigational when the member does not meet the stated clinical criteria, has clinical and epidemiological features strongly suggesting a viral etiology, or when results will not influence clinical management.

    • Document at least one qualifying feature, such as acute pharyngitis, fever, tonsillopharyngeal inflammation or exudates, palatal petechiae, anterior cervical lymphadenitis, or scarlatiniform rash.
    • Confirm that clinical and epidemiological features do not strongly suggest a viral etiology, such as cough, rhinorrhea, hoarseness, or oral ulcers.
    • Confirm that results will influence clinical management.
    Denial Risk

    Large multiplex panel criteria must be met

    Syndromic or multiplex respiratory panels with 6 or more targets are investigational unless the member has an acute respiratory infection with immunocompromise, severe pneumonia, or an airway-disease exacerbation and the results will influence clinical management.

    • Document signs or symptoms of an acute respiratory infection in the outpatient setting.
    • Document at least one qualifying condition: immunocompromise, severe pneumonia, or exacerbation of airway disease.
    • Confirm that results will influence clinical management.
    Denial Risk

    Small viral panel criteria must be met

    SARS-CoV-2, RSV, influenza A/B, and multiplex respiratory viral panels with 5 or fewer targets are investigational when the member does not have outpatient signs or symptoms of an acute respiratory infection or when results will not influence clinical management.

    • Document signs or symptoms of an acute respiratory infection in the outpatient setting.
    • Confirm that results will influence clinical management.
    SARS-CoV-2
    Included viral targetRespiratory syncytial virus (RSV)
    Included viral targetInfluenza A/B